Establishment of a pharmaceutical standardized interview concerning biosimilars of infliximab in the daycare clinic of the Gastroenterology Department for patients affected by inflammatory bowel disease

Abstract n°: 4CPS-144

Pôle Pharmacie, Hôpital Saint-Eloi, CHU Montpellier1 ; Pôle Pharmacie, Hôpital Lapeyronie, CHU Montpellier1 ; Pôle digestive, Hôpital Saint-Eloi, CHU de Montpellier1

Background

Anti-TNF monoclonal antibodies such as infliximab effectively treat inflammatory bowel disease (IBD). Currently they are recommended after failure or contraindication of corticosteroid/immunosuppressive therapy. The use of infliximab’s biosimilars is an important question due to the economy of health cost and in the objective of improving health care.

Objectives

• Evaluate the patients treated by the reference product’s knowledge about biosimilars
• Assess the number of patients who would accept switching to a biosimilar
• Realize an economic analysis about the switch

Methods

Evaluate the patient’s knowledge about biosimilar
Give them the missing information
Collect the patient’s opinion about the switch
Transmission of the information to the prescribers
Follow up of the prescriptions during the next cycles
Economic analysis of the data

Results

Patient’s opinion about switching to biosimilar

- Pro 39%
- Against 38%
- Do not know 23%

Cause of concern

- Efficiency + Tolerance 35%
- Efficiency 30%
- Tolerance 17%
- Need a medical advice 15%
- Inquire alone 3%

Interviewed population : 33 women / 31 men (average age 44 years old)
• 92 % of patients had never received any information about biosimilars
• Among 64 patients, 15 were against a switch to biosimilar, 25 had no opinion and 24 were favourable to the switch

However, in only 6 of the 24 patients in favor of the switch, the therapeutic modification was carried out by the doctor

Concerning the doubts emitted by the patients:

- 68% relating to the efficiency and/or the tolerance of the biosimilar compared to the Reference product
- 30% want to talk to their doctor
- 1 patient decided to inquire by himself

Discussion and Conclusions

• The investment of the pharmacy in the daycare clinic of the gastroenterology allowed a saving of 1,856 € per year, or 0.7% of the budget devoted to the reference product.
• That said : More than a third of the patients were favorable to a biosimilar relay → possible savings of € 8128 per year, or 2.9% of the budget dedicated to biosimilars. An explanation for this is the lack of transmission of information to the prescriber.
• Finally, concerning patients who are reluctant or undecided about the relay, the main reasons given concern the tolerance and/or efficiency of the biosimilar. This encourages us to increase our efforts to inform patients about these new specialties and to consider setting up a pharmacist position in this service to provide specific information.

Key words : IBD, Infliximab, Biosimilar, Reference product, Pharmaceutical interview

ATC code: L04 - Immunosuppressive agents

If switch of all patients If switch of all favourable patients Economy currently realized

Potential cost saving in € per year

If switch of all patients If switch of all favourable patients Economy currently realized

Praticable economy in % of the budget assigned to Reference product

- Over the year, the achieved switches allowed to save 1,856 € (out of 8,128 € possible if the patient’s opinions were respected), or 0.7% of the Reference product service budget.
- If all patients switched to biosimilar, a saving of 21,750 € could be realized